Semin Thromb Hemost 2015; 41(06): 572-581
DOI: 10.1055/s-0035-1556589
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective

Jecko Thachil
1   Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
15 August 2015 (online)

Abstract

Platelets are well recognized as a key cell component of the hemostatic system. Recently, several additional functions have been discovered for these blood cells but most importantly in the process of inflammation. Numerous research groups have demonstrated crucial roles for platelets in the pathogenesis of varied clinical conditions where inflammation is important. Alterations in both platelet number and function have been observed with these different conditions. The relevance of these findings is their therapeutic implications through simple antiplatelet therapy to more complex, as yet clinically untrialed options, like interfering with platelet–leukocyte or platelet–endothelial interaction. This review focuses on how platelets are relevant in inflammatory conditions with an impetus on the clinical aspects.

 
  • References

  • 1 Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7 (1) 23-38
  • 2 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114 (12) 2367-2374
  • 3 Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127 (3) 514-525
  • 4 Dahlbäck B. Coagulation and inflammation—close allies in health and disease. Semin Immunopathol 2012; 34 (1) 1-3
  • 5 Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation 2005; 12 (3) 247-258
  • 6 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115 (12) 3378-3384
  • 7 Gawaz M, Brand K, Dickfeld T , et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148 (1) 75-85
  • 8 Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54 (8) 669-677
  • 9 Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43 (5) 331-340
  • 10 Ho-Tin-Noé B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost 2011; 9 (Suppl. 01) 56-65
  • 11 Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34 (2) 255-265
  • 12 Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53 (4) 387-394
  • 13 Thachil J. The difficult distinction between antiphospholipid syndrome and thrombotic thrombocytopenic purpura. Br J Haematol 2010; 149 (2) 294-295
  • 14 Thachil J. Lessons from acute pancreatitis-induced thrombotic thrombocytopenic purpura. Eur J Intern Med 2009; 20 (8) 739-743
  • 15 van Mourik JA, Boertjes R, Huisveld IA , et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94 (1) 179-185
  • 16 Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205 (9) 2065-2074
  • 17 Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81 (1) 1-7
  • 18 Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21 (2) 99-111
  • 19 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85 (2) 195-204
  • 20 Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131 (3) 191-197
  • 21 von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97 (5) 704-713
  • 22 Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83 (5) 1069-1078
  • 23 Corken A, Russell S, Dent J, Post SR, Ware J. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscler Thromb Vasc Biol 2014; 34 (5) 996-1001
  • 24 Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147 (6) 1713-1726
  • 25 Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47 (13) 2170-2175
  • 26 Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201 (6) 871-879
  • 27 Hamad OA, Bäck J, Nilsson PH, Nilsson B, Ekdahl KN. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol 2012; 946: 185-205
  • 28 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110 (5) 894-902
  • 29 Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology (Am Soc Hematol Educ Program) 2011; 2011 (11) 51-61
  • 30 Smid J, Braun-Dullaeus R, Gawaz M, Langer HF. Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiol 2009; 5 (3) 285-296
  • 31 Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol 2000; 157 (1) 69-74
  • 32 Trowbridge EA, Martin JF, Slater DN. Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res 1982; 28 (4) 461-475
  • 33 Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet 1987; 2 (8573) 1434-1435
  • 34 Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2009; 40 (2) 123-134
  • 35 Schneider RC, Zapol WM, Carvalho AC. Platelet consumption and sequestration in severe acute respiratory failure. Am Rev Respir Dis 1980; 122 (3) 445-451
  • 36 Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976; 61 (5) 585-589
  • 37 Peng X, Hassoun PM, Sammani S , et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169 (11) 1245-1251
  • 38 Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116 (12) 3211-3219
  • 39 O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med 2006; 173 (5) 483-490
  • 40 Gross S, Luckey C. The oxygen tension-platelet relationship in cystic fibrosis. Am Rev Respir Dis 1969; 100 (4) 513-517
  • 41 O'Sullivan BP, Linden MD, Frelinger III AL , et al. Platelet activation in cystic fibrosis. Blood 2005; 105 (12) 4635-4641
  • 42 Abraham EH, Sterling KM, Kim RJ , et al. Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis. Blood Cells Mol Dis 2001; 27 (1) 165-180
  • 43 Ciabattoni G, Davì G, Collura M , et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med 2000; 162 (4, Pt 1): 1195-1201
  • 44 Page C, Pitchford S. Platelets and allergic inflammation. Clin Exp Allergy 2014; 44 (7) 901-913
  • 45 Dürk T, Duerschmied D, Müller T , et al. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. Am J Respir Crit Care Med 2013; 187 (5) 476-485
  • 46 Yoshida A, Ohba M, Wu X, Sasano T, Nakamura M, Endo Y. Accumulation of platelets in the lung and liver and their degranulation following antigen-challenge in sensitized mice. Br J Pharmacol 2002; 137 (2) 146-152
  • 47 Svensson Holm AC, Bengtsson T, Grenegård M, Lindström EG. Platelet membranes induce airway smooth muscle cell proliferation. Platelets 2011; 22 (1) 45-55
  • 48 Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013; 382 (9896) 984-994
  • 49 Caudrillier A, Kessenbrock K, Gilliss BM , et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012; 122 (7) 2661-2671
  • 50 Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119 (11) 3450-3461
  • 51 Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108 (6) 1024-1027
  • 52 Maclay JD, McAllister DA, Johnston S , et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66 (9) 769-774
  • 53 Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for anti-platelet therapy?. Thorax Published Online First 2014; 69 (7) 609-615
  • 54 Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011; 31 (2) 153-164
  • 55 Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis?. Platelets 2008; 19 (2) 146-154
  • 56 Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 46 (6) 1498-1503
  • 57 Ertenli I, Kiraz S, Arici M , et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 1998; 25 (6) 1054-1058
  • 58 Mac Mullan PA, Peace AJ, Madigan AM, Tedesco AF, Kenny D, McCarthy GM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology (Oxford) 2010; 49 (2) 240-245
  • 59 Boilard E, Nigrovic PA, Larabee K , et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327 (5965) 580-583
  • 60 Cloutier N, Paré A, Farndale RW , et al. Platelets can enhance vascular permeability. Blood 2012; 120 (6) 1334-1343
  • 61 Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007; 19 (6) 574-579
  • 62 Dees C, Akhmetshina A, Zerr P , et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208 (5) 961-972
  • 63 Pauling JD, O'Donnell VB, Mchugh NJ. The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis. Platelets 2013; 24 (7) 503-515
  • 64 Maugeri N, Franchini S, Campana L , et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012; 45 (8) 584-587
  • 65 Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005; 64 (9) 1366-1369
  • 66 Zhao H, Li S, Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets 2010; 21 (5) 380-385
  • 67 Garcia-Romo GS, Caielli S, Vega B , et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3 (73) 73ra20
  • 68 Clark SR, Ma AC, Tavener SA , et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13 (4) 463-469
  • 69 Fuchs TA, Brill A, Duerschmied D , et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
  • 70 Lood C, Eriksson S, Gullstrand B , et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus—a possible link to venous thrombosis?. Lupus 2012; 21 (13) 1423-1432
  • 71 Delmas Y, Viallard JF, Solanilla A , et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney Int 2005; 68 (5) 2068-2078
  • 72 Tanaka T, Kuroiwa T, Ikeuchi H , et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol 2002; 13 (10) 2488-2496
  • 73 Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014; 20 (12) 3180-3190
  • 74 Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968; 68 (5) 1013-1021
  • 75 Thachil J. Extreme thrombocytosis—an unusual presentation of inflammatory bowel disease. Intern Med 2008; 47 (13) 1255-1257
  • 76 Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE 2012; 7 (4) e34520
  • 77 Kulnigg-Dabsch S, Schmid W, Howaldt S , et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 2013; 19 (8) 1609-1616
  • 78 Danese S, de la Motte C, Sturm A , et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124 (5) 1249-1264
  • 79 Danese S, Scaldaferri F, Vetrano S , et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007; 56 (9) 1248-1256
  • 80 Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10 (4) 361-372
  • 81 Andoh A, Tsujikawa T, Hata K , et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005; 100 (9) 2042-2048
  • 82 Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008; 5: 27
  • 83 Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115 (17) 3632-3639
  • 84 Bush AI, Martins RN, Rumble B , et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990; 265 (26) 15977-15983
  • 85 Zhang W, Huang W, Jing F. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med 2013; 4: 141-147
  • 86 Ciabattoni G, Porreca E, Di Febbo C , et al. Determinants of platelet activation in Alzheimer's disease. Neurobiol Aging 2007; 28 (3) 336-342
  • 87 Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol 2007; 254 (4) 548-549
  • 88 Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J ; AD2000 Collaborative Group. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008; 7 (1) 41-49